» Articles » PMID: 36582241

Thrombotic Microangiopathy Mediates Poor Prognosis Among Lupus Nephritis Complement Lectin and Alternative Pathway Activation

Overview
Journal Front Immunol
Date 2022 Dec 30
PMID 36582241
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk factors for renal survival between patients with or without TMA in LN cohorts.

Methods: We included 79 patients with biopsy-proven LN-associated TMA and matched the same number of LN patients without TMA as the control group. The deposition of mannose binding lectin (MBL), MBL-associated serine proteases 1/3 (MASP1/3), complement factor B (CFB), complement factor D (CFD), C4d, and von Willebrand factor (VWF) in renal tissue was assessed by immunohistochemistry and immunofluorescence. Besides, co-localization of C5b-9 and CD34 was detected by confocal microscopy.

Results: In our retrospective cohort, the incidence of acute kidney injury (30% vs. 14%, p = 0.013), acute hemodialysis (35% vs. 5%, p < 0.001), and interstitial fibrosis (43% vs. 13%, p < 0.001) is higher in the TMA, compared with the control group. Despite aggressive steroids pulse, plasma exchange, and immunosuppressive therapy among TMA group, they still had significantly inferior 3-year renal survival rates (68% vs. 89%, p = 0.002) than those in the non-TMA group. COX regression analysis identified that TMA (HR 4.807, 95% CI [2.052, 11.263], p < 0.001) is a risk factor in LN. MBL, MASP1/3, CFB, CFD, C4d, and VWF deposited along the glomerulus among LN, while TMA had stronger staining intensity and deposition. The co-localized expression of CD34 and C5b-9 in the endothelial cells was also observed in the renal tissues.

Conclusions: TMA is an independent risk factor for renal survival in LN patients. Moreover, LP and AP activation are involved in the pathogenesis of LN-associated TMA.

Citing Articles

Early administration of caplacizumab combined with plasma exchange for thrombotic microangiopathy due to malignant hypertension: a case report.

Okawa H, Wada Y, Takeuchi K, Motohashi T, Abe T, Uchitsubo R CEN Case Rep. 2025; .

PMID: 40029564 DOI: 10.1007/s13730-025-00978-3.


Complement-Mediated Hemolytic Uremic Syndrome Due to MCP/CD46 Mutation: A Case Report.

Abdeen A, Al-Nusair J, Samardali M, Alshal M, Al-Astal A, Khitan Z J Investig Med High Impact Case Rep. 2025; 13:23247096251316364.

PMID: 39871416 PMC: 11773514. DOI: 10.1177/23247096251316364.


Role of complement factor D in cardiovascular and metabolic diseases.

Kong Y, Wang N, Tong Z, Wang D, Wang P, Yang Q Front Immunol. 2024; 15:1453030.

PMID: 39416783 PMC: 11479899. DOI: 10.3389/fimmu.2024.1453030.


Lupus Nephritis from Pathogenesis to New Therapies: An Update.

Roveta A, Parodi E, Brezzi B, Tunesi F, Zanetti V, Merlotti G Int J Mol Sci. 2024; 25(16).

PMID: 39201667 PMC: 11354900. DOI: 10.3390/ijms25168981.


Early-onset lupus nephritis.

Peyronel F, Rossi G, Palazzini G, Odone L, Errichiello C, Emmi G Clin Kidney J. 2024; 17(8):sfae212.

PMID: 39135943 PMC: 11318049. DOI: 10.1093/ckj/sfae212.


References
1.
Nisihara R, Magrini F, Mocelin V, Messias-Reason I . Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients. Hum Immunol. 2013; 74(8):907-10. DOI: 10.1016/j.humimm.2013.04.030. View

2.
Grumach A, Kirschfink M . Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol. 2014; 61(2):110-7. DOI: 10.1016/j.molimm.2014.06.030. View

3.
Lunz Macedo A, Isaac L . Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway. Front Immunol. 2016; 7:55. PMC: 4764694. DOI: 10.3389/fimmu.2016.00055. View

4.
Shen Y, Chen X, Sun C, Dai M, Yan Y, Yang C . Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases. Lupus. 2010; 19(10):1195-203. DOI: 10.1177/0961203310368409. View

5.
Bao L, Haas M, Quigg R . Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol. 2010; 22(2):285-95. PMC: 3029901. DOI: 10.1681/ASN.2010060647. View